dr. janjigian discusses afatinib and cetuximab for patients with egfr-mutant lung cancer
Published 10 years ago • 1K plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
8:38
afatinib plus cetuximab in resistant non-small cell lung cancer
-
1:35
dr. bunn discusses afatinib for patients with egfr mutation
-
0:51
dr. west discusses afatinib and cetuximab combination in nsclc
-
1:25
dr. bunn discusses afatinib in lung cancer
-
1:25
dr. chachoua on afatinib for exon 19 mutation in lung cancer
-
2:14
lux-lung 7: phase 2b trial of first-line afatinib versus gefitinib for egfr mutation-positive nsclc
-
5:47
egfr tkis for upfront treatment of nsclc
-
8:47
study of 693 nsclc patients treated with afatinib
-
1:30
dr. langer on afatinib for advanced non-small cell lung cancer
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
-
9:27
post-hoc analysis of sequential afatinib and osimertinib in nsclc patients
-
0:45
dr. corey langer discusses afatinib in egfr-positive nsclc
-
4:56
upfront bevacizumab and cetuximab compared in metastatic colorectal cancer
-
0:51
dr. tianhong (tina) li reviews the lux-lung 3 trial afatinib data
-
1:16
dr. scagliotti on treating egfr-mutated tumors with afatinib
-
2:07
dr. janjigian on immunotherapy combinations in gastric cancer
-
1:44
dr. oxnard on delaying second-line treatment in egfr-mutant lung cancer
-
1:13
dr. lenz on breakthrough designation of encorafenib, binimetinib, and cetuximab in braf crc
-
1:00
dr. janjigian on conducting msi testing in gastric cancer